The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Jan M.M. Walboomers, Marcel V. Jacobs, M. Michele Manos et al. · The Journal of Pathology · 1999 · 9K citations · Full text

Medicine, Oncology, Pathology +16

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

Núbia Muñóz, F. Xavier Bosch, Sílvia de Sanjosé et al. · New England Journal of Medicine · 2003 · 6.3K citations · Full text

Medicine, Oncology, Pathology +17

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2004 · 1.6K citations

Veterinary Medicine, Infectious Diseases, Preventive Medicine +16

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2006 · 1.6K citations · Full text

Veterinary Medicine, Immunology, Oncology +16

A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler et al. · New England Journal of Medicine · 2002 · 1.6K citations · Full text

Medicine, Oncology, Preventive Medicine +17